ENDPOINTS

FDA OKs new label expansions for Dupixent and Incyte's Monjuvi

Plus, news about Novartis' Mariana Oncology: FDA approves Dupixent in rare autoimmune disease: The approval is for bullous pemphigoid, a condition in which the immune system attacks ...

Jun 20, 2025 - 15:20
 0
FDA OKs new label expansions for Dupixent and Incyte's Monjuvi
Plus, news about Novartis' Mariana Oncology: FDA approves Dupixent in rare autoimmune disease: The approval is for bullous pemphigoid, a condition in which the immune system attacks ...
Read More

Tags:

Previous Article

Early-stage investor Syncona readjusts priorities due to bleak biotech market

Next Article

Many elite athletes live below the poverty line. Tax-deductible donations won't ...

Related Posts

Bayer Q1 earnings: 2,000 jobs cut as it homes in on year-end rehaul target

Bayer Q1 earnings: 2,000 jobs cut as it homes in on yea...

May 13, 2025  0

Stelara biosimilars look to gain traction, helped by recent lessons from Humira

Stelara biosimilars look to gain traction, helped by re...

May 19, 2025  0

Roche's venture arm chief to step down in 2026; AstraZeneca obesity leader has retired

Roche's venture arm chief to step down in 2026; AstraZe...

Jun 20, 2025  0